{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0747","upperLimit":"0.2507","value":"0.1627"},{"groupId":"OG001","lowerLimit":"0.0407","upperLimit":"0.3431","value":"0.1919"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"70"}],"units":"Participants"}],"description":"Probability of no relapse, secondary malignancy, or death after 3 years in the study.","dispersionType":"95% Confidence Interval","groups":[{"description":"IMC-A12 + Multi-agent intensive chemotherapy regimen.","id":"OG000","title":"IMC-A12"},{"description":"Add temozolomide to vincristine/irinotecan cycles.","id":"OG001","title":"Temozolomide"}],"paramType":"NUMBER","populationDescription":"9 participants who were ineligible or did not receive treatment were excluded.","reportingStatus":"POSTED","timeFrame":"3 years","title":"Event-Free Survival","type":"PRIMARY","unitOfMeasure":"Probability"}